IL-15/IL-21 armored GPC3-specific CAR-T cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IL-15/IL-21 armored GPC3-specific CAR-T cell therapy, covering 2026-04-06 to 2026-04-06. Get the full timeline:
Most recent: Clinical Trial Update: Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors [Phase 1]